{"id":1021641,"date":"2026-11-16T16:49:13","date_gmt":"2026-11-16T21:49:13","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/ibio-announces-new-preclinical-data-across-obesity-and-cardiometabolic-portfolio-at-multiple-scientific-conferences\/"},"modified":"2026-11-16T16:49:13","modified_gmt":"2026-11-16T21:49:13","slug":"ibio-announces-new-preclinical-data-across-obesity-and-cardiometabolic-portfolio-at-multiple-scientific-conferences","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/ibio-announces-new-preclinical-data-across-obesity-and-cardiometabolic-portfolio-at-multiple-scientific-conferences\/","title":{"rendered":"iBio Announces New Preclinical Data Across Obesity and Cardiometabolic Portfolio at Multiple Scientific Conferences"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"center\">\n        <em>ObesityWeek 2026 data from obese non-human primates showed sustained Activin E suppression and a 2.3% vehicle-adjusted reduction in body weight from baseline with IBIO-610 at week 28.<\/em>\n      <\/p>\n<p align=\"center\">\n        <em>Amylin program data demonstrating reduced food intake in rats to be presented at PEGS Europe and the Amylin-Based Therapeutics Summit<\/em>\n      <\/p>\n<p align=\"center\">\n        <em>Together, the findings highlight the potential of iBio\u2019s antibody discovery platform to generate highly specific candidates against distinct targets<\/em>\n      <\/p>\n<p align=\"justify\">SAN DIEGO, Nov.  16, 2026  (GLOBE NEWSWIRE) &#8212; iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology company developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary diseases, today announced extended preclinical data from a non-human primate (NHP) study of IBIO-610, potentially a first-in-class Activin E antibody candidate, presented at ObesityWeek 2026, as well as preclinical data from its amylin program to be presented at PEGS Europe 2026 and the Amylin-Based Therapeutics Summit.<\/p>\n<p align=\"justify\">\u201cThese data demonstrate the power of our AI-enabled antibody discovery platform to generate potent, highly specific molecules against challenging targets,\u201d said Martin Brenner, DVM, Ph.D., chief executive officer and chief scientific officer of iBio. \u201cThe sustained effects observed in our NHP study strengthen our belief in IBIO-610\u2019s potential to offer a differentiated approach to long-term weight management. Durable Activin E suppression, reductions in fat mass while generally maintaining lean mass, and the newly observed reduction in body weight provide a more comprehensive perspective of how this approach may improve the quality of weight loss. Beyond IBIO-610, our amylin program has taken an important step forward, demonstrating high selectivity for amylin receptors and reduced food intake in a preclinical model. We believe this selective approach has the potential to improve the balance of efficacy and tolerability and look forward to evaluating it in further studies. By pursuing multiple distinct mechanisms, we have the opportunity to build a complementary portfolio of medicines with the potential to extend the cardiometabolic benefits of weight loss beyond current therapies.\u201d<\/p>\n<p align=\"justify\">\n        <strong>IBIO-610 Activin E Data presented at ObesityWeek 2026<\/strong><br \/>\n        <br \/>The new data for iBio\u2019s long-acting Activin E-targeting antibody, IBIO-610, builds on previously reported findings from an obese NHP study, extending observations through 28 weeks.<\/p>\n<p align=\"justify\">The study included obese NHPs receiving IBIO-610 (n=5) or vehicle (n=6). IBIO-610 was initially administered every eight weeks, followed by more frequent dosing and a dose-free period.<\/p>\n<p>\n        <strong>Key findings:<\/strong>\n      <\/p>\n<ul type=\"disc\">\n<li style=\"text-align:justify\">IBIO-610 reduced weight gain despite continued high-fat feeding, with body weight beginning to diverge from the vehicle group around Week 18 and reaching a 2.3% difference by Week 28.\n<\/li>\n<li style=\"text-align:justify\">At Week 24, total body fat was 9.6% lower, abdominal subcutaneous fat 16.6% lower, and visceral fat 10.96% lower compared with vehicle, while lean mass was generally maintained.\n<\/li>\n<li style=\"text-align:justify\">Near-complete suppression of active Activin E was observed through week 28.\n<\/li>\n<\/ul>\n<p align=\"justify\">These findings build on previously reported <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=e7DSMLGT733yqzz3QsV1kQct_eTW6cmOpOez3rlKmRiYWfprUA7ITvCNV6_RVR2oOcufR6F6D3uUjHv-n0Hn56T_k9-Z3tJtPFRFTyfJmVvZclCMG-GVS3eYxwpkY-yNm6NAi_lM7NVDQ3bzTUyEmQQ8qKjgHCZXYrKF8SapBPQvg6dx9W0KrvmZjyY1cduQ_-4S36n08n_IAlVHJLXSXuRuLHAzWe0D30UluGpdW1GHK3AQ6y-FftHhxAA144uypl_Qw1qm6tGY9XGUp9cmDsDkgaoNxAeta-xeNqp58AE2iDoeVxSvULAL5bOPPbUJ\" rel=\"nofollow\" target=\"_blank\">data<\/a> from the NHP study and further support IBIO-610\u2019s potential to promote fat-selective effects while maintaining lean mass.<\/p>\n<p>\n        <strong>Amylin Program Data to Be Presented at PEGS Europe and the Amylin-Based Therapeutics Summit<\/strong>\n      <\/p>\n<p align=\"justify\">iBio\u2019s amylin program combines a receptor-targeting antibody with a fused peptide agonist and demonstrated highly selective activation of amylin receptors 1 and 3. The findings highlight the platform\u2019s ability to generate highly specific antibodies against challenging targets and support the development of a potential long-acting amylin therapeutic.<\/p>\n<p>\n        <strong>Key findings:<\/strong>\n      <\/p>\n<ul type=\"disc\">\n<li style=\"text-align:justify\">In vitro, iBio\u2019s antibody-peptide fusion selectively bound and activated amylin receptors 1 and 3, with minimal binding to or activation of the calcitonin receptor alone.\n<\/li>\n<li style=\"text-align:justify\">In a single-dose study in lean rats, the rats dosed with iBio\u2019s selective amylin receptor agonist had reduced food intake over 24 hours compared with vehicle.\n<\/li>\n<\/ul>\n<p align=\"justify\">iBio plans to advance selective amylin receptor agonists into further preclinical studies in diet-induced obesity models.<\/p>\n<p>\n        <strong>Presentation Details:<\/strong>\n      <\/p>\n<p>\n        <strong><br \/>\n          <u>ObesityWeek 2026<\/u><br \/>\n        <\/strong><br \/>\n        <br \/>\n        <strong>Title:<\/strong> Deep, Durable Activin E Suppression by Antibody Blockade Drives Fat-Selective Effects in Obese Non-Human Primates<br \/><strong>Format:<\/strong> Poster<br \/><strong>Date and time:<\/strong> Sunday, November 15, 2026, 2:30\u20133:30 p.m. ET<br \/><strong>Presenter:<\/strong> Cory Schwartz<br \/><strong>Location:<\/strong> Gaylord National Resort &amp; Convention Center, National Harbor, Maryland<\/p>\n<p>\n        <strong><br \/>\n          <u>PEGS Europe 2026<\/u><br \/>\n        <\/strong><br \/>\n        <br \/>\n        <strong>Title:<\/strong> Beyond Peptides: Engineering GPCR Agonists for Next-Generation Cardiometabolic Therapeutics<br \/><strong>Format:<\/strong> Oral presentation<br \/><strong>Date and time:<\/strong> Thursday, November 19, 2026, at 11:15 a.m. WET<br \/><strong>Presenter:<\/strong> Cody Moore<br \/><strong>Location:<\/strong> Lisbon Congress Center, Lisbon, Portugal<\/p>\n<p>\n        <strong><br \/>\n          <u>Amylin-Based Therapeutics Summit<\/u><br \/>\n        <\/strong><br \/>\n        <br \/>\n        <strong>Title:<\/strong> Decoding Amylin Receptor Specificity to Engineer a More Precise, Long-Acting Therapeutic<br \/><strong>Format: <\/strong>Presentation<br \/><strong>Presenter:<\/strong> Cody Moore<br \/><strong>Date and time:<\/strong> Wednesday, December 2, 2026, at 1:30 p.m. ET<br \/><strong>Location:<\/strong> Wyndham Boston Beacon Hill<\/p>\n<p>\n        <strong>Title:<\/strong> Navigating the Efficacy\u2013Tolerability Trade-off: Linking Half-Life, Dosing and Clinical Outcomes to Define Amylin\u2019s Competitive Advantage<br \/><strong>Format: <\/strong>Workshop<br \/><strong>Leader:<\/strong> Cory Schwartz<br \/><strong>Date and time:<\/strong> Tuesday, December 1, 2026, at 1:00 p.m. ET<br \/><strong>Location:<\/strong> Wyndham Boston Beacon Hill<\/p>\n<p align=\"justify\">\n        <strong>About iBio, Inc.<br \/><\/strong>iBio (Nasdaq: IBIO) is a clinical-stage biotechnology company developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary diseases, cancer, and other hard-to-treat diseases. Combining advanced antibody engineering with AI-driven discovery, iBio is advancing a differentiated pipeline designed to deliver sustained therapeutic effects and address significant unmet medical needs. iBio\u2019s mission is to transform drug discovery, accelerate development timelines, and unlock new possibilities in precision medicine.<\/p>\n<p>For more information, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=8kKgIW8ujcg7omch3JMBfIih8mD5PYuWE9GI7Jnlgb89W2DgTJ9jlLDLmS8wZeUWRrXUaIrTvj0nSPgGUAdiCtC6xJnWPEE0sC-3buS4X2s=\" rel=\"nofollow\" target=\"_blank\">www.ibioinc.com<\/a> or follow us on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Q4kwN7obLUtH_vYaOOYPsnHOAn--EnrJXv-Jtm5Rs5w2q9TgIFnPd3v8zmcMb5jCkkzRUC21BJO3nK4rnvBFIE-OT0Rv5oYBHQESfS9uABM=\" rel=\"nofollow\" target=\"_blank\">LinkedIn<\/a>.<\/p>\n<p>\n        <strong>Forward-Looking Statements<\/strong>\n      <\/p>\n<p align=\"justify\">This press release contains forward-looking statements within the meaning of the federal securities laws. These statements include, among others, statements regarding the potential of iBio\u2019s antibody discovery platform to generate highly specific candidates against distinct targets; IBIO-610 potentially being a first-in-class Activin E antibody candidate; IBIO-610\u2019s potential to offer a differentiated approach to long-term weight management; durable Activin E suppression, reductions in fat mass while generally maintaining lean mass, and the newly observed reduction in body weight providing a more comprehensive perspective of how the approach may improve the quality of weight loss; the amylin program\u2019s approach having the potential to improve the balance of efficacy and tolerability; iBio evaluating the selective approach in further studies; having the opportunity to build a complementary portfolio of medicines with the potential to extend the cardiometabolic benefits of weight loss beyond current therapies; the findings further supporting IBIO-610\u2019s potential to promote fat-selective effects while maintaining lean mass; the development of a potential long-acting amylin therapeutic iBio plans to advance selective amylin receptor agonists into further preclinical studies in diet-induced obesity models. These statements reflect iBio\u2019s current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially, including risks associated with the possibility that preclinical findings will not be replicated in humans, iBIO\u2019s ability to successfully develop products, including products for long-term weight management; durable Activin E suppression, reductions in fat mass while generally maintaining lean mass and iBio\u2019s ability to obtain regulatory approval or any of its products, and the other risks described in iBio\u2019s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended June 30, 2026, and subsequent filings.<\/p>\n<p align=\"justify\">Forward-looking statements speak only as of the date of this release. iBio undertakes no obligation to update them except as required by law.<\/p>\n<p>\n        <strong>Investor Contact<\/strong><br \/>\n        <br \/>Matt Beck<br \/>astr partners<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=I_RLnn0kI7_oE1X-tDgFwP1A1J7D-k5JNDOogOQXBw0wYj3HscUIwCmB7_G_gXaJTiqZlyxugrCeFWqRAftwQl9qN8YphNMlQGaScK28Gv3UCHFCo69ENTPfsRQ9rebA\" rel=\"nofollow\" target=\"_blank\">matthew.beck@astrpartners.com<\/a><br \/>(917) 415-1750<\/p>\n<p>\n        <strong>Media Contact<\/strong><br \/>\n        <br \/>Jason Braco, Ph.D.<br \/>Valence Communications<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Lj1JsfXbqbgnCs0AaifqDqPVWJZwxgCBhRVLRoxoKktIx0Euvu9gxoX06aE83TmsxfbD3RaERB2fpjfxKuPRERA3v1a5kqlmzYI08BZKENM=\" rel=\"nofollow\" target=\"_blank\">jason@valencecomms.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3ODgxNCM3OTY5MjAxIzIwODc1NzM=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/YTNkM2E5NWYtNjZkYS00ZWFkLWJlNTMtMzE0ZTgyNjI3ODliLTEwOTkxNDQtMjAyNi0xMS0xNi1lbg==\/tiny\/iBio-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>ObesityWeek 2026 data from obese non-human primates showed sustained Activin E suppression and a 2.3% vehicle-adjusted reduction in body weight from baseline with IBIO-610 at week 28. Amylin program data demonstrating reduced food intake in rats to be presented at PEGS Europe and the Amylin-Based Therapeutics Summit Together, the findings highlight the potential of iBio\u2019s antibody discovery platform to generate highly specific candidates against distinct targets SAN DIEGO, Nov. 16, 2026 (GLOBE NEWSWIRE) &#8212; iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology company developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary diseases, today announced extended preclinical data from a non-human primate (NHP) study of IBIO-610, potentially a first-in-class Activin E antibody candidate, presented at ObesityWeek 2026, as well as preclinical &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ibio-announces-new-preclinical-data-across-obesity-and-cardiometabolic-portfolio-at-multiple-scientific-conferences\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;iBio Announces New Preclinical Data Across Obesity and Cardiometabolic Portfolio at Multiple Scientific Conferences&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1021641","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>iBio Announces New Preclinical Data Across Obesity and Cardiometabolic Portfolio at Multiple Scientific Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ibio-announces-new-preclinical-data-across-obesity-and-cardiometabolic-portfolio-at-multiple-scientific-conferences\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"iBio Announces New Preclinical Data Across Obesity and Cardiometabolic Portfolio at Multiple Scientific Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"ObesityWeek 2026 data from obese non-human primates showed sustained Activin E suppression and a 2.3% vehicle-adjusted reduction in body weight from baseline with IBIO-610 at week 28. Amylin program data demonstrating reduced food intake in rats to be presented at PEGS Europe and the Amylin-Based Therapeutics Summit Together, the findings highlight the potential of iBio\u2019s antibody discovery platform to generate highly specific candidates against distinct targets SAN DIEGO, Nov. 16, 2026 (GLOBE NEWSWIRE) &#8212; iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology company developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary diseases, today announced extended preclinical data from a non-human primate (NHP) study of IBIO-610, potentially a first-in-class Activin E antibody candidate, presented at ObesityWeek 2026, as well as preclinical &hellip; Continue reading &quot;iBio Announces New Preclinical Data Across Obesity and Cardiometabolic Portfolio at Multiple Scientific Conferences&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/ibio-announces-new-preclinical-data-across-obesity-and-cardiometabolic-portfolio-at-multiple-scientific-conferences\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-11-16T21:49:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3ODgxNCM3OTY5MjAxIzIwODc1NzM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ibio-announces-new-preclinical-data-across-obesity-and-cardiometabolic-portfolio-at-multiple-scientific-conferences\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ibio-announces-new-preclinical-data-across-obesity-and-cardiometabolic-portfolio-at-multiple-scientific-conferences\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"iBio Announces New Preclinical Data Across Obesity and Cardiometabolic Portfolio at Multiple Scientific Conferences\",\"datePublished\":\"2026-11-16T21:49:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ibio-announces-new-preclinical-data-across-obesity-and-cardiometabolic-portfolio-at-multiple-scientific-conferences\\\/\"},\"wordCount\":1159,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ibio-announces-new-preclinical-data-across-obesity-and-cardiometabolic-portfolio-at-multiple-scientific-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3ODgxNCM3OTY5MjAxIzIwODc1NzM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ibio-announces-new-preclinical-data-across-obesity-and-cardiometabolic-portfolio-at-multiple-scientific-conferences\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ibio-announces-new-preclinical-data-across-obesity-and-cardiometabolic-portfolio-at-multiple-scientific-conferences\\\/\",\"name\":\"iBio Announces New Preclinical Data Across Obesity and Cardiometabolic Portfolio at Multiple Scientific Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ibio-announces-new-preclinical-data-across-obesity-and-cardiometabolic-portfolio-at-multiple-scientific-conferences\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ibio-announces-new-preclinical-data-across-obesity-and-cardiometabolic-portfolio-at-multiple-scientific-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3ODgxNCM3OTY5MjAxIzIwODc1NzM=\",\"datePublished\":\"2026-11-16T21:49:13+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ibio-announces-new-preclinical-data-across-obesity-and-cardiometabolic-portfolio-at-multiple-scientific-conferences\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ibio-announces-new-preclinical-data-across-obesity-and-cardiometabolic-portfolio-at-multiple-scientific-conferences\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ibio-announces-new-preclinical-data-across-obesity-and-cardiometabolic-portfolio-at-multiple-scientific-conferences\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3ODgxNCM3OTY5MjAxIzIwODc1NzM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3ODgxNCM3OTY5MjAxIzIwODc1NzM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ibio-announces-new-preclinical-data-across-obesity-and-cardiometabolic-portfolio-at-multiple-scientific-conferences\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"iBio Announces New Preclinical Data Across Obesity and Cardiometabolic Portfolio at Multiple Scientific Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"iBio Announces New Preclinical Data Across Obesity and Cardiometabolic Portfolio at Multiple Scientific Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/ibio-announces-new-preclinical-data-across-obesity-and-cardiometabolic-portfolio-at-multiple-scientific-conferences\/","og_locale":"en_US","og_type":"article","og_title":"iBio Announces New Preclinical Data Across Obesity and Cardiometabolic Portfolio at Multiple Scientific Conferences - Market Newsdesk","og_description":"ObesityWeek 2026 data from obese non-human primates showed sustained Activin E suppression and a 2.3% vehicle-adjusted reduction in body weight from baseline with IBIO-610 at week 28. Amylin program data demonstrating reduced food intake in rats to be presented at PEGS Europe and the Amylin-Based Therapeutics Summit Together, the findings highlight the potential of iBio\u2019s antibody discovery platform to generate highly specific candidates against distinct targets SAN DIEGO, Nov. 16, 2026 (GLOBE NEWSWIRE) &#8212; iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology company developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary diseases, today announced extended preclinical data from a non-human primate (NHP) study of IBIO-610, potentially a first-in-class Activin E antibody candidate, presented at ObesityWeek 2026, as well as preclinical &hellip; Continue reading \"iBio Announces New Preclinical Data Across Obesity and Cardiometabolic Portfolio at Multiple Scientific Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/ibio-announces-new-preclinical-data-across-obesity-and-cardiometabolic-portfolio-at-multiple-scientific-conferences\/","og_site_name":"Market Newsdesk","article_published_time":"2026-11-16T21:49:13+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3ODgxNCM3OTY5MjAxIzIwODc1NzM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ibio-announces-new-preclinical-data-across-obesity-and-cardiometabolic-portfolio-at-multiple-scientific-conferences\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ibio-announces-new-preclinical-data-across-obesity-and-cardiometabolic-portfolio-at-multiple-scientific-conferences\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"iBio Announces New Preclinical Data Across Obesity and Cardiometabolic Portfolio at Multiple Scientific Conferences","datePublished":"2026-11-16T21:49:13+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ibio-announces-new-preclinical-data-across-obesity-and-cardiometabolic-portfolio-at-multiple-scientific-conferences\/"},"wordCount":1159,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ibio-announces-new-preclinical-data-across-obesity-and-cardiometabolic-portfolio-at-multiple-scientific-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3ODgxNCM3OTY5MjAxIzIwODc1NzM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ibio-announces-new-preclinical-data-across-obesity-and-cardiometabolic-portfolio-at-multiple-scientific-conferences\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/ibio-announces-new-preclinical-data-across-obesity-and-cardiometabolic-portfolio-at-multiple-scientific-conferences\/","name":"iBio Announces New Preclinical Data Across Obesity and Cardiometabolic Portfolio at Multiple Scientific Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ibio-announces-new-preclinical-data-across-obesity-and-cardiometabolic-portfolio-at-multiple-scientific-conferences\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ibio-announces-new-preclinical-data-across-obesity-and-cardiometabolic-portfolio-at-multiple-scientific-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3ODgxNCM3OTY5MjAxIzIwODc1NzM=","datePublished":"2026-11-16T21:49:13+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ibio-announces-new-preclinical-data-across-obesity-and-cardiometabolic-portfolio-at-multiple-scientific-conferences\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/ibio-announces-new-preclinical-data-across-obesity-and-cardiometabolic-portfolio-at-multiple-scientific-conferences\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ibio-announces-new-preclinical-data-across-obesity-and-cardiometabolic-portfolio-at-multiple-scientific-conferences\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3ODgxNCM3OTY5MjAxIzIwODc1NzM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3ODgxNCM3OTY5MjAxIzIwODc1NzM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ibio-announces-new-preclinical-data-across-obesity-and-cardiometabolic-portfolio-at-multiple-scientific-conferences\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"iBio Announces New Preclinical Data Across Obesity and Cardiometabolic Portfolio at Multiple Scientific Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1021641","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1021641"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1021641\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1021641"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1021641"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1021641"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}